Name | Calpain Inhibitor III |
Synonyms | CS-1705 MDL 28170 Z-VAL-PHE-CHO Z-VAL-PHE-ALDEHYDE Calpain Inhibitor III CALPAIN INHIBITOR III CARBOBENZOXY-VALINYL-PHENYLALANINAL CARBOBEZOXY-VALINYL-PHENYLALANINALZ-VAL-PHE-CHO |
CAS | 88191-84-8 |
EINECS | 618-124-4 |
InChI | InChI=1/C22H26N2O4/c1-16(2)20(24-22(27)28-15-18-11-7-4-8-12-18)21(26)23-19(14-25)13-17-9-5-3-6-10-17/h3-12,14,16,19-20H,13,15H2,1-2H3,(H,23,26)(H,24,27)/t19-,20-/m0/s1 |
Molecular Formula | C22H26N2O4 |
Molar Mass | 382.45 |
Density | 1.153±0.06 g/cm3(Predicted) |
Boling Point | 595.6±50.0 °C(Predicted) |
Flash Point | 314°C |
Solubility | DMSO: 26mg/mL |
Vapor Presure | 3.74E-14mmHg at 25°C |
Appearance | White lyophilized solid |
Color | White |
pKa | 11.05±0.46(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
Refractive Index | 1.554 |
In vitro study | MDL-28170 significantly and time-dependently improved the recovery of synaptic responses without hypoxic depolarization after prolonged moderate hypoxia in hippocampal slices. MDL-28170 dose-dependently inhibited brain cysteine protease activity (Ki = 0.01 μm in vitro). |
In vivo study | Treatment with MDL-28170 (50 mg/kg, i.p.) completely prevents the striatal damage in four animals in each of the two treatment groups. The numbers of necrotic neurons are reduced by 85% and 68% in animals in which MDL-28170 injections are initiated at 0.5 and 3 h of recirculation, respectively. MDL-28170 (30 mg/kg, i.p.) reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. MDL-28170 (10 mg/kg, i.p.) significantly improves nerve function parameters in diabetic rats. MDL-28170 (3 and 10 mg/kg, i.p.) improves nociceptive behavior in diabetic rats. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |